Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell 2Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 5Rituximab 4Mycophenolic Acid 4Cyclosporine 4Cyclophosphamide 4romidepsin 3Whole-Body Irradiation 3Methotrexate 3Everolimus 3Busulfan 3durvalumab 2Vorinostat 2Vincristine 2Tacrolimus 2Photopheresis 2Immunoglobulin G 2Filgrastim 2Etoposide 2Disulfides 2Brentuximab Vedotin 2Bortezomib 2veliparib 1tremelimumab 1tazarotenic acid 1tazarotene 1poly ICLC 1pembrolizumab 1navitoclax 1mogamulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Cutaneous × AFM13 × Clear all
NCT03192202 2023-07-20

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Columbia University

Phase 1/2 Completed
18 enrolled 9 charts
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡